KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 103 filers reported holding KEROS THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $15,071,302 | -20.7% | 472,751 | 0.0% | 0.01% | -11.1% |
| Q2 2023 | $18,995,136 | -5.9% | 472,751 | 0.0% | 0.01% | -10.0% |
| Q1 2023 | $20,186,468 | -11.1% | 472,751 | 0.0% | 0.01% | -16.7% |
| Q4 2022 | $22,701,503 | +27.6% | 472,751 | -0.1% | 0.01% | +20.0% |
| Q3 2022 | $17,794,000 | +36.2% | 472,998 | +0.0% | 0.01% | +66.7% |
| Q2 2022 | $13,066,000 | -39.1% | 472,880 | +19.8% | 0.01% | -33.3% |
| Q1 2022 | $21,463,000 | -7.1% | 394,677 | -0.0% | 0.01% | +12.5% |
| Q4 2021 | $23,094,000 | +47.9% | 394,688 | +0.0% | 0.01% | +33.3% |
| Q3 2021 | $15,613,000 | -6.9% | 394,660 | -0.0% | 0.01% | 0.0% |
| Q2 2021 | $16,764,000 | +4.7% | 394,725 | +51.7% | 0.01% | -14.3% |
| Q1 2021 | $16,014,000 | -12.7% | 260,179 | +0.0% | 0.01% | -12.5% |
| Q4 2020 | $18,349,000 | – | 260,126 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 321,300 | $12,087,000 | 4.99% |
| First Light Asset Management, LLC | 598,213 | $22,505,000 | 2.28% |
| Nantahala Capital Management | 845,692 | $31,815,000 | 2.06% |
| CHI Advisors LLC | 200,229 | $7,533,000 | 2.03% |
| Fairmount Funds Management LLC | 272,498 | $10,251,000 | 1.80% |
| Altium Capital Management LP | 88,000 | $3,311,000 | 1.21% |
| Orbimed Advisors | 1,679,417 | $63,180,000 | 1.17% |
| SPHERA FUNDS MANAGEMENT LTD. | 206,819 | $7,781,000 | 1.08% |
| Parkman Healthcare Partners LLC | 99,927 | $3,759,000 | 1.07% |
| Soleus Capital Management, L.P. | 146,000 | $5,493,000 | 0.75% |